Lutrate Depot Trimestral 22,5 mg polvo y disolvente para suspensión inyectable de liberación prolongada, Verzenios 150 mg film-coated tablets, Femara 2.5 mg Tablets, Arimidex® 1 mg film-coated tablets, Zoladex 10,8 mg implantat, Aromasil 25 mg comprimidos recubiertos, Verzenios 100 mg film-coated tablets, Zoladex 3,6 mg implantat, Kisqali 200 mg film-coated tablets, Lutrate Depot Mensual 3,75 mg polvo y disolvente para suspensión inyectable de liberación prolongada, Verzenios 50 mg film-coated tablets
GEICAM/2023-09
Quick answer
Lutrate Depot Trimestral 22,5 mg polvo y disolvente para suspensión inyectable de liberación prolongada, Verzenios 150 mg film-coated tablets, Femara 2.5 mg Tablets, Arimidex® 1 mg film-coated tablets, Zoladex 10,8 mg implantat, Aromasil 25 mg comprimidos recubiertos, Verzenios 100 mg film-coated tablets, Zoladex 3,6 mg implantat, Kisqali 200 mg film-coated tablets, Lutrate Depot Mensual 3,75 mg polvo y disolvente para suspensión inyectable de liberación prolongada, Verzenios 50 mg film-coated tablets for Early Breast Cancer is a Approved program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cancer Prevention Pharma (Ireland) Limited
- Indication
- Early Breast Cancer
- Phase
- Approved
- Modality
- small_molecule
- Status
- active